KDR

(redirected from VEGFR2)
Also found in: Acronyms.

KDR

A gene on chromosome 4q11-q12 that encodes a vascular endothelial growth factor receptor known as kinase insert domain receptor, which is a type-III receptor tyrosine kinase. KDR is the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting.

Molecular pathology
KDR mutations have been linked to infantile capillary haemangiomas.
Mentioned in ?
References in periodicals archive ?
We have identified an important new mechanism that regulates VEGFR2 transport in vascular cells," corresponding author Michael Simons, professor of medicine and cell biology, and director of the cardiovascular research center at Yale School of Medicine said.
Lenvatinib, discovered and developed by Eisai, is an oral multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors (VEGFR1 (FLT1), VEGFR2 (KDR) and VEGFR3 (FLT4)), in addition to other proangiogenic and oncogenic pathway-related RTKs (including fibroblast growth factor (FGF) receptors FGFR1, 2, 3 and 4; the platelet-derived growth factor (PDGF) receptor PDGFRalpha; KIT; and RET) involved in tumor proliferation.
With its demonstrated connection to a broad host of cancers, among other disease areas, VEGFR2 is a target that we expect to help drive the expansion of Silence's RNAi therapeutics pipeline.
NASDAQ:EXEL) today announced the initiation of two investigator-sponsored trials (ISTs) of cabozantinib, which simultaneously targets MET, VEGFR2 and RET.
Cabozantinib is a potent targeted therapy that inhibits MET, VEGFR2, and RET, all of which play an important role in the biology of medullary thyroid cancer.
Fruquintinib is designed to selectively inhibit VEGF receptors, namely VEGFR1, VEGFR2 and VEGFR3.
Advaxis, will report on anti-tumor effects and antigen specific immune responses in mouse models generated by an Lm-LLO based immunotherapy consisting of two antigens, cHER2 and VEGFR2.
About Lenvatinib Lenvatinib, discovered and developed by Eisai, is a receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors (VEGFR1 (FLT1), VEGFR2 (KDR) and VEGFR3 (FLT4)), in addition to other oncogenic pathway-related tyrosine kinases including fibroblast growth factor receptors (FGFR), the platelet-derived growth factor (PDGF) receptor PDGFR[eth], KIT and RET.
a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix' VeriStrat[R] test in a Phase 3 non-small cell lung cancer (NSCLC) study of Kadmon's KD019, a reversible tyrosine kinase inhibitor (TKI) targeting EGFR, HER2, VEGFR2 & 3, and SRC.